Impact of aromatase inhibitors on adhesion formation in a rat model.
OBJECTIVE
To investigate the antiadhesion potential of tamoxifen and anastrozole in a rat uterine horn model.


METHODS
Experimental animal study.


METHODS
University animal laboratory.


METHODS
Forty-five female Wistar albino rats.


METHODS
We examined the effects of tamoxifen and anastrozole to reduce the extent and severity of postoperative adhesions in a rat uterine horn model: the control group received no therapy while the second and third groups received 500 mug/day tamoxifen and 0.2 mg/kg/day anastrazole, respectively, through an enteric tube, starting 5 days before surgery. These protocols were continued for 14 days after the surgery until the rats were killed.


METHODS
Adhesions were scored according to their extent and severity, and specimens were also evaluated and scored histologically according to the following features: inflammation, fibroblastic activities, foreign body reaction, collagen formation, and vascular proliferation.


RESULTS
Anastrozole had the lowest mean adhesion scores, and these scores were significantly different from those of the controls. However, there were no statistically significant differences between control and tamoxifen groups and between tamoxifen and anastrozole groups. Histologic scores were lowest in the anastrozole group, which were statistically different from those of the tamoxifen and anastrozole groups, whereas scores of the control group were not statistically different from those of the tamoxifen group.


CONCLUSIONS
Anastrazole decreased postsurgical adhesion scores by both visual scores and histologic analyses in a rat model. Further experimental and clinical trials are required to confirm these results.
Kaya
Umit
U
Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey.
Oktem
Mesut
M
Zeyneloglu
Hulusi B
HB
Ozen
Ozlem
O
Kuscu
Esra
E
D000077384:Anastrozole; D000818:Animals; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D016207:Cytokines / Q000502:physiology; D004195:Disease Models, Animal; D005260:Female; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control*; D014230:Triazoles / Q000627:therapeutic use*; D014591:Uterine Diseases / Q000517:prevention & control*; D014599:Uterus / Q000601:surgery*
D047072:Aromatase Inhibitors; D016207:Cytokines; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D017258:Medroxyprogesterone Acetate